nccn-guidelines
(2)
ArteraAI
ArteraAI is a precision medicine company building multimodal AI tests that personalize cancer therapy. Its flagship ArteraAI Prostate Test is the first AI-enabled predictive and prognostic biomarker recommended in the NCCN Guidelines for localized prostate cancer, validated across five Phase 3 trials.
Andre Esteva
Andre Esteva, PhD, is the co-founder and CEO of ArteraAI, a medical AI company whose test for personalizing prostate cancer therapy is included in NCCN clinical guidelines, reimbursed by Medicare, and deployed internationally. A Stanford-trained AI scientist whose Nature cover paper first demonstrated that AI could match dermatologists at diagnosing skin cancer, Esteva has co-founded four companies with a combined market cap of $2.2B. Named to TIME100 Health 2025 and Modern Healthcare's 40 Under 40 for 2025, he leads a company that raised $175M total and was named a TIME 2024 Best Invention.